Identifying fast-onset antidepressants using rodent models

Molecular Psychiatry

Volumn 22, Issue 5, 2017, Pages 656-665

  Ramaker, M J ^a   Dulawa, S C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; KETAMINE; METABOTROPIC RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PINDOLOL; RAPASTINEL; SCOPOLAMINE; SEROTONIN AGONIST; SEROTONIN ANTAGONIST;

ANTIDEPRESSANT ACTIVITY; CHRONIC STRESS; DEPRESSION; DRUG IDENTIFICATION; ELECTROCONVULSIVE THERAPY; FORCED SWIM TEST; HYPOPHAGIA; LEARNED HELPLESSNESS; NONHUMAN; NOVELTY SUPPRESSED FEEDING TEST; OLFACTORY BULBECTOMY; PRIORITY JOURNAL; REVIEW; RODENT MODEL; SLEEP DEPRIVATION; VALIDITY; ANIMAL; DEPRESSIVE DISORDER; DISEASE MODEL; METABOLISM; RODENT;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; RODENTIA;

EID: 85015652391     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2017.36     Document Type: Review

References (179)

1. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-3105.
2. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006;354:1243-1252.
3. Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry 2007;68:1062-1070.
4. Papakostas GI. Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry 2009;70(Suppl 6): 16-25.
5. Fava M, Rush AJ, Alpert JE, Balasubramani GK, Wisniewski SR, Carmin CN et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR∗D report. Am J Psychiatry 2008;165:342-351.
6. Hendrie C, Pickles A, Stanford SC, Robinson E. The failure of the antidepressant drug discovery process is systemic. J Psychopharmacol 2013;27:407-413, discussion 413-416.
7. Nutt D, Goodwin G. ECNP Summit on the future of CNS drug research in Europe 2011: report prepared for ECNP by David Nutt and Guy Goodwin. Eur Neuropsychopharmacol 2011;21:495-499.
8. Healy D. The Antidepressant Era. Harvard University Press, 1997;334.
9. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry J Ment Sci 1979;134:382-389.
10. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
11. Zimmerman M, Posternak MA, Chelminski I. Is it time to replace the hamilton depression rating scale as the primary outcome measure in treatment studies of depression? J Clin Psychopharmacol 2005;25:105-110.
12. Bech P, Allerup P, Gram LF, Reisby N, Rosenberg R, Jacobsen O et al. The hamilton depression scale. Acta Psychiatr Scand 1981;63:290-299.
13. Shiroma PR, Thuras P, Johns B, Lim KO. Emotion recognition processing as early predictor of response to 8-week citalopram treatment in late-life depression. Int J Geriatr Psychiatry 2014;29:1132-1139.
14. Harmer CJ, Shelley NC, Cowen PJ, Goodwin GM. Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Am J Psychiatry 2004;161:1256-1263.
15. Katz MM, Tekell JL, Bowden CL, Brannan S, Houston JP, Berman N et al. Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology 2004;29:566-579.
16. Segman RH, Shapira B, Gorfine M, Lerer B. Onset and time course of antidepressant action: psychopharmacological implications of a controlled trial of electroconvulsive therapy. Psychopharmacology 1995;119:440-448.
17. Wu JC, Bunney WE. The biological basis of an antidepressant response to sleep deprivation and relapse: review and hypothesis. Am J Psychiatry 1990;147:14-21.
18. Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63:856-864.
19. Preskorn S, Macaluso M, Mehra DOV, Zammit G, Moskal JR, Burch RM et al. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J Psychiatr Pract 2015;21:140-149.
20. Furey ML, Drevets WC. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry 2006;63:1121-1129.
21. Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 2016;533:481-486.
22. Geyer MA, Markou A. Animal models of psychiatric disorders. In: Watson S (ed.). Psychopharmacology: The Fourth Generation of Progress CD-ROM Version 3, Lippincott Williams & Wilkins, 2000. Available at https://www.acnp.org/g4/ GN401000076/CH.html (Accessed on 13 April 2016).
23. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003;301:805-809.
24. Dulawa SC, Holick KA, Gundersen B, Hen R. Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 2004;29:1321-1330.
25. Hyman SE. Back to basics: luring industry back into neuroscience. Nat Neurosci 2016;19:1383-1384.
26. Markou A, Chiamulera C, Geyer MA, Tricklebank M, Steckler T. Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology 2009;34:74-89.
27. Gorodetzky CW, Grudzinskas C. Involving the pharmaceutical and biotech communities in medication development for substance abuse. Pharmacol Ther 2005;108:109-118.
28. De Pablo JM, Ortiz-Caro J, Sanchez-Santed F, Guillamón A. Effects of diazepam, pentobarbital, scopolamine and the timing of saline injection on learned immobility in rats. Physiol Behav 1991;50:895-899.
29. Browne RG. Effects of antidepressants and anticholinergics in a mouse "behavioral despair" test. Eur J Pharmacol 1979;58:331-334.
30. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng P et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011;475:91-95.
31. Li N, Lee B, Liu R-J, Banasr M, Dwyer JM, Iwata M et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010;329:959-964.
32. Lu Y, Wang C, Xue Z, Li C, Zhang J, Zhao X et al. PI3K/AKT/mTOR signalingmediated neuropeptide VGF in the hippocampus of mice is involved in the rapid onset antidepressant-like effects of GLYX-13. Int J Neuropsychopharmacol 2015;18.
33. Yang B, Zhang J-C, Han M, Yao W, Yang C, Ren Q et al. Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression. Psychopharmacology 2016;233:3647-3657.
34. Burgdorf J, Zhang X, Nicholson KL, Balster RL, Leander JD, Stanton PK et al. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology 2013;38:729-742.
35. Voleti B, Navarria A, Liu R-J, Banasr M, Li N, Terwilliger R et al. Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol Psychiatry 2013;74:742-749.
36. Lepack AE, Fuchikami M, Dwyer JM, Banasr M, Duman RS. BDNF release is required for the behavioral actions of ketamine. Int J Neuropsychopharmacol 2015;18:1.
37. Maeng S, Zarate CA, Du J, Schloesser RJ, McCammon J, Chen G et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alphaamino- 3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008;63:349-352.
38. Caldarone BJ, Zachariou V, King SL. Rodent models of treatment-resistant depression. Eur J Pharmacol 2015;753:51-65.
39. Kelly JP, Wrynn AS, Leonard BE. The olfactory bulbectomized rat as a model of depression: an update. Pharmacol Ther 1997;74:299-316.
40. Song C, Leonard BE. The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev 2005;29:627-647.
41. Redmond AM, Kelly JP, Leonard BE. Behavioural and neurochemical effects of dizocilpine in the olfactory bulbectomized rat model of depression. Pharmacol Biochem Behav 1997;58:355-359.
42. Drevets WC, Price JL, Furey ML. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct 2008;213:93-118.
43. Cryan JF, Mombereau C. In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice. Mol Psychiatry 2004;9:326-357.
44. O'Connor WT, Earley B, Leonard BE. Antidepressant properties of the triazolobenzodiazepines alprazolam and adinazolam: studies on the olfactory bulbectomized rat model of depression. Br J Clin Pharmacol 1985;19(Suppl 1): 49S-56S.
45. Smith WT, Glaudin V. Double-blind efficacy and safety study comparing adinazolam mesylate and placebo in depressed inpatients. Acta Psychiatr Scand 1986;74:238-245.
46. Kennedy SH, de Groot J, Ralevski E, Reed K. A comparison of adinazolam and desipramine in the treatment of major depression. Int Clin Psychopharmacol 1991;6:65-76.
47. Amsterdam JD, Kaplan M, Potter L, Bloom L, Rickels K. Adinazolam, a new triazolobenzodiazepine, and imipramine in the treatment of major depressive disorder. Psychopharmacology 1986;88:484-488.
48. Hicks F, Robins E, Murphy GE. Comparison of adinazolam, amitriptyline, and placebo in the treatment of melancholic depression. Psychiatry Res 1988;23:221-227.
49. Berlim MT, Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry 2007;52:46-54.
50. Holubova K, Kleteckova L, Skurlova M, Ricny J, Stuchlik A, Vales K. Rapamycin blocks the antidepressant effect of ketamine in task-dependent manner. Psychopharmacology 2016;233:2077-2097.
51. Maturana MJ, Pudell C, Targa ADS, Rodrigues LS, Noseda ACD, Fortes MH et al. REM sleep deprivation reverses neurochemical and other depressive-like alterations induced by olfactory bulbectomy. Mol Neurobiol 2015;51:349-360.
52. Cryan JF, McGrath C, Leonard BE, Norman TR. Combining pindolol and paroxetine in an animal model of chronic antidepressant action-can early onset of action be detected? Eur J Pharmacol 1998;352:23-28.
53. Maier SF. Learned helplessness and animal models of depression. Prog Neuropsychopharmacol Biol Psychiatry 1984;8:435-446.
54. Opal MD, Klenotich SC, Morais M, Bessa J, Winkle J, Doukas D et al. Serotonin 2C receptor antagonists induce fast-onset antidepressant effects. Mol Psychiatry 2014;19:1106-1114.
55. Lucas G, Rymar VV, Du J, Mnie-Filali O, Bisgaard C, Manta S et al. Serotonin(4) (5-HT(4)) receptor agonists are putative antidepressants with a rapid onset of action. Neuron 2007;55:712-725.
56. van Riezen H, Schnieden H, Wren AF. Olfactory bulb ablation in the rat: behavioural changes and their reversal by antidepressant drugs. Br J Pharmacol 1977;60:521-528.
57. Porsolt RD, Anton G, Blavet N, Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 1978;47:379-391.
58. Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977;229:327-336.
59. Lucki I, Dalvi A, Mayorga AJ. Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology 2001;155:315-322.
60. Jiao J, Nitzke AM, Doukas DG, Seiglie MP, Dulawa SC. Antidepressant response to chronic citalopram treatment in eight inbred mouse strains. Psychopharmacology 2011;213:509-520.
61. Holick KA, Lee DC, Hen R, Dulawa SC. Behavioral effects of chronic fluoxetine in BALB/cJ mice do not require adult hippocampal neurogenesis or the serotonin 1A receptor. Neuropsychopharmacology 2008;33:406-417.
62. Licznerski P, Duman RS. Remodeling of axo-spinous synapses in the pathophysiology and treatment of depression. Neuroscience 2013;251:33-50.
63. Can A, Blackwell RA, Piantadosi SC, Dao DT, O'Donnell KC, Gould TD. Antidepressant-like responses to lithium in genetically diverse mouse strains. Genes Brain Behav 2011;10:434-443.
64. Guilloux J-P, Mendez-David I, Pehrson A, Guiard BP, Repérant C, Orvoën S et al. Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. Neuropharmacology 2013;73:147-159.
65. Shanahan NA, Velez LP, Masten VL, Dulawa SC. Essential role for orbitofrontal serotonin 1B receptors in obsessive-compulsive disorder-like behavior and serotonin reuptake inhibitor response in mice. Biol Psychiatry 2011;70:1039-1048.
66. Nagatani T, Yamamoto T, Sugihara T, Ueki S. The effect of agonists at the GABAbenzodiazepine receptor complex on the duration of immobility of mice in the forced swimming test. Eur J Pharmacol 1987;142:17-22.
67. Li N, Liu R-J, Dwyer JM, Banasr M, Lee B, Son H et al. Glutamate N-methyl-Daspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 2011;69:754-761.
68. Garcia LS, Comim CM, Valvassori SS, Réus GZ, Andreazza AC, Stertz L et al. Chronic administration of ketamine elicits antidepressant-like effects in rats without affecting hippocampal brain-derived neurotrophic factor protein levels. Basic Clin Pharmacol Toxicol 2008;103:502-506.
69. Chen J, Peng L-H, Luo J, Liu L, Lv F, Li P et al. Effects of low-dose ketamine combined with propofol on phosphorylation of AMPA receptor GluR1 subunit and GABAA receptor in hippocampus of stressed rats receiving electroconvulsive shock. J ECT 2015;31:50-56.
70. Jiang Y, Zhu J. Effects of sleep deprivation on behaviors and abnormal hippocampal BDNF/miR-10B expression in rats with chronic stress depression. Int J Clin Exp Pathol 2015;8:586-593.
71. Yalcin I, Aksu F, Belzung C. Effects of desipramine and tramadol in a chronic mild stress model in mice are altered by yohimbine but not by pindolol. Eur J Pharmacol 2005;514:165-174.
72. Wu L-M, Han H, Wang Q-N, Hou H-L, Tong H, Yan X-B et al. Mifepristone repairs region-dependent alteration of synapsin I in hippocampus in rat model of depression. Neuropsychopharmacology 2007;32:2500-2510.
73. Sun J-D, Liu Y, Yuan Y-H, Li J, Chen N-H. Gap junction dysfunction in the prefrontal cortex induces depressive-like behaviors in rats. Neuropsychopharmacology 2012;37:1305-1320.
74. D'Aquila PS, Newton J, Willner P. Diurnal variation in the effect of chronic mild stress on sucrose intake and preference. Physiol Behav 1997;62:421-426.
75. Forbes NF, Stewart CA, Matthews K, Reid IC. Chronic mild stress and sucrose consumption: validity as a model of depression. Physiol Behav 1996;60:1481-1484.
76. Dulawa SC, Hen R. Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test. Neurosci Biobehav Rev 2005;29:771-783.
77. Bodnoff SR, Suranyi-Cadotte B, Quirion R, Meaney MJ. A comparison of the effects of diazepam versus several typical and atypical anti-depressant drugs in an animal model of anxiety. Psychopharmacology 1989;97:277-279.
78. Bodnoff SR, Suranyi-Cadotte B, Aitken DH, Quirion R, Meaney MJ. The effects of chronic antidepressant treatment in an animal model of anxiety. Psychopharmacology 1988;95:298-302.
79. Carrier N, Kabbaj M. Sex differences in the antidepressant-like effects of ketamine. Neuropharmacology 2013;70:27-34.
80. Koike H, Iijima M, Chaki S. Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists. Neuropharmacology 2011;61:1419-1423.
81. Gideons ES, Kavalali ET, Monteggia LM. Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses. Proc Natl Acad Sci USA 2014;111:8649-8654.
82. Iijima M, Fukumoto K, Chaki S. Acute and sustained effects of a metabotropic glutamate 5 receptor antagonist in the novelty-suppressed feeding test. Behav Brain Res 2012;235:287-292.
83. Mazella J, Pétrault O, Lucas G, Deval E, Béraud-Dufour S, Gandin C et al. Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design. PLoS Biol 2010;8: e1000355.
84. Pascual-Brazo J, Castro E, Díaz A, Valdizán EM, Pilar-Cuéllar F, Vidal R et al. Modulation of neuroplasticity pathways and antidepressant-like behavioural responses following the short-term (3 and 7 days) administration of the 5-HT, receptor agonist RS67333. Int J Neuropsychopharmacol 2012;15:631-643.
85. Zanos P, Piantadosi SC, Wu H-Q, Pribut HJ, Dell MJ, Can A et al. The prodrug 4-chlorokynurenine causes ketamine-like antidepressant effects, but not side effects, by NMDA/glycineb-site inhibition. J Pharmacol Exp Ther 2015;355:76-85.
86. Fukumoto K, Chaki S. Involvement of serotonergic system in the effect of a metabotropic glutamate 5 receptor antagonist in the novelty-suppressed feeding test. J Pharmacol Sci 2015;127:57-61.
87. Fukumoto K, Iijima M, Chaki S. Serotonin-1A receptor stimulation mediates effects of a metabotropic glutamate 2/3 receptor antagonist, 2S-2-amino-2- (1S, 2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic acid (LY341495), and an N-methyl-D-aspartate receptor antagonist, ketamine, in the novelty-suppressed feeding test. Psychopharmacology 2014;231:2291-2298.
88. Koike H, Fukumoto K, Iijima M, Chaki S. Role of BDNF/TrkB signaling in antidepressant-like effects of a group II metabotropic glutamate receptor antagonist in animal models of depression. Behav Brain Res 2013;238:48-52.
89. Stan TL, Sousa VC, Zhang X, Ono M, Svenningsson P. Lurasidone and fluoxetine reduce novelty-induced hypophagia and NMDA receptor subunit and PSD-95 expression in mouse brain. Eur Neuropsychopharmacol 2015;25:1714-1722.
90. Karlsson R-M, Choe JS, Cameron HA, Thorsell A, Crawley JN, Holmes A et al. The neuropeptide Y Y1 receptor subtype is necessary for the anxiolytic-like effects of neuropeptide Y, but not the antidepressant-like effects of fluoxetine, in mice. Psychopharmacology 2008;195:547-557.
91. Andreasen JT, Fitzpatrick CM, Larsen M, Skovgaard L, Nielsen SD, Clausen RP et al. Differential role of AMPA receptors in mouse tests of antidepressant and anxiolytic action. Brain Res 2015;1601:117-126.
92. Louderback KM, Wills TA, Muglia LJ, Winder DG. Knockdown of BNST GluN2Bcontaining NMDA receptors mimics the actions of ketamine on novelty-induced hypophagia. Transl Psychiatry 2013;3: e331.
93. Berton O, McClung CA, Dileone RJ, Krishnan V, Renthal W, Russo SJ et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 2006;311:864-868.
94. Brachman RA, McGowan JC, Perusini JN, Lim SC, Pham TH, Faye C et al. Ketamine as a prophylactic against stress-induced depressive-like behavior. Biol Psychiatry 2015;79:776-786.
95. Donahue RJ, Muschamp JW, Russo SJ, Nestler EJ, Carlezon WA. Effects of striatal ΔFosB overexpression and ketamine on social defeat stress-induced anhedonia in mice. Biol Psychiatry 2014;76:550-558.
96. Zhang Q, Guo F, Fu Z-W, Zhang B, Huang C-G, Li Y. Timosaponin derivative YY-23 acts as a non-competitive NMDA receptor antagonist and exerts a rapid antidepressant-like effect in mice. Acta Pharmacol Sin 2016;37:166-176.
97. Geoffroy M, Scheel-Krüger J, Christensen AV. Effect of imipramine in the "learned helplessness" model of depression in rats is not mimicked by combinations of specific reuptake inhibitors and scopolamine. Psychopharmacology 1990;101:371-375.
98. Beurel E, Song L, Jope RS. Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol Psychiatry 2011;16:1068-1070.
99. Biedermann S, Weber-Fahr W, Zheng L, Hoyer C, Vollmayr B, Gass P et al. Increase of hippocampal glutamate after electroconvulsive treatment: a quantitative proton MR spectroscopy study at 9.4 T in an animal model of depression. World J Biol Psychiatry 2012;13:447-457.
100. Sartorius A, Vollmayr B, Neumann-Haefelin C, Ende G, Hoehn M, Henn FA. Specific creatine rise in learned helplessness induced by electroconvulsive shock treatment. Neuroreport 2003;14:2199-2201.
101. Sherman AD, Sacquitne JL, Petty F. Specificity of the learned helplessness model of depression. Pharmacol Biochem Behav 1982;16:449-454.
102. Cryan JF, Mombereau C, Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 2005;29:571-625.
103. Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol 1997;8:523-532.
104. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995;15:7539-7547.
105. Thoenen H. Neurotrophins and neuronal plasticity. Science 1995;270:593-598.
106. Lee B, Sur B, Shim J, Hahm D-H, Lee H. Acupuncture stimulation improves scopolamine-induced cognitive impairment via activation of cholinergic system and regulation of BDNF and CREB expressions in rats. BMC Complement Altern Med 2014;14:338.
107. Konar A, Shah N, Singh R, Saxena N, Kaul SC, Wadhwa R et al. Protective role of Ashwagandha leaf extract and its component withanone on scopolamineinduced changes in the brain and brain-derived cells. PloS ONE 2011;6: e27265.
108. Chen W, Cheng X, Chen J, Yi X, Nie D, Sun X et al. Lycium barbarum polysaccharides prevent memory and neurogenesis impairments in scopolaminetreated rats. PloS ONE 2014;9: e88076.
109. Kotani S, Yamauchi T, Teramoto T, Ogura H. Donepezil, an acetylcholinesterase inhibitor, enhances adult hippocampal neurogenesis. Chem Biol Interact 2008;175:227-230.
110. Shi Z, Chen L, Li S, Chen S, Sun X, Sun L et al. Chronic scopolamine-injectioninduced cognitive deficit on reward-directed instrumental learning in rat is associated with CREB signaling activity in the cerebral cortex and dorsal hippocampus. Psychopharmacology 2013;230:245-260.
111. Heo Y-M, Shin M-S, Kim S-H, Kim T-W, Baek S-B, Baek S-S. Treadmill exercise ameliorates disturbance of spatial learning ability in scopolamine-induced amnesia rats. J Exerc Rehabil 2014;10:155-161.
112. Thome J, Sakai N, Shin K, Steffen C, Zhang YJ, Impey S et al. cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J Neurosci 2000;20:4030-4036.
113. Vaidya VA, Siuciak JA, Du F, Duman RS. Hippocampal mossy fiber sprouting induced by chronic electroconvulsive seizures. Neuroscience 1999;89:157-166.
114. Acosta-Peña E, Camacho-Abrego I, Melgarejo-Gutiérrez M, Flores G, Drucker-Colín R, García-García F. Sleep deprivation induces differential morphological changes in the hippocampus and prefrontal cortex in young and old rats. Synapse 2015;69:15-25.
115. Tang J, Xue W, Xia B, Ren L, Tao W, Chen C et al. Involvement of normalized NMDA receptor and mTOR-related signaling in rapid antidepressant effects of Yueju and ketamine on chronically stressed mice. Sci Rep 2015;5:13573.
116. Fumagalli F, Pasini M, Sartorius A, Scherer R, Racagni G, Riva MA et al. Repeated electroconvulsive shock (ECS) alters the phosphorylation of glutamate receptor subunits in the rat hippocampus. Int J Neuropsychopharmacol 2010;13:1255-1260.
117. Gao X, Zhuang F-Z, Qin S-J, Zhou L, Wang Y, Shen Q-F et al. Dexmedetomidine protects against learning and memory impairments caused by electroconvulsive shock in depressed rats: involvement of the NMDA receptor subunit 2B (NR2B)- ERK signaling pathway. Psychiatry Res 2016;243:446-452.
118. Xie M, Li C, He C, Yang L, Tan G, Yan J et al. Short-term sleep deprivation disrupts the molecular composition of ionotropic glutamate receptors in entorhinal cortex and impairs the rat spatial reference memory. Behav Brain Res 2016;300:70-76.
119. Xie M, Yan J, He C, Yang L, Tan G, Li C et al. Short-term sleep deprivation impairs spatial working memory and modulates expression levels of ionotropic glutamate receptor subunits in hippocampus. Behav Brain Res 2015;286:64-70.
120. Zhou W, Dong L, Wang N, Shi J, Yang J, Zuo Z et al. Akt mediates GSK-3β phosphorylation in the rat prefrontal cortex during the process of ketamine exerting rapid antidepressant actions. Neuroimmunomodulation 2014;21:183-188.
121. West CHK, Weiss JM. Effects of chronic antidepressant drug administration and electroconvulsive shock on activity of dopaminergic neurons in the ventral tegmentum. Int J Neuropsychopharmacol 2011;14:201-210.
122. Tsen P, El Mansari M, Blier P. Effects of repeated electroconvulsive shocks on catecholamine systems: electrophysiological studies in the rat brain. Synape 2013;67:716-727.
123. Belujon P, Grace AA. Restoring mood balance in depression: ketamine reverses deficit in dopamine-dependent synaptic plasticity. Biol Psychiatry 2014;76:927-936.
124. Hand TH, Hu XT, Wang RY. Differential effects of acute clozapine and haloperidol on the activity of ventral tegmental (A10) and nigrostriatal (A9) dopamine neurons. Brain Res 1987;415:257-269.
125. Schilström B, Ivanov VB, Wiker C, Svensson TH. Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors. Neuropsychopharmacology 2007;32:43-53.
126. Yoshida K, Higuchi H, Kamata M, Yoshimoto M, Shimizu T, Hishikawa Y. Dopamine releasing response in rat striatum to single and repeated electroconvulsive shock treatment. Prog Neuropsychopharmacol Biol Psychiatry 1997;21:707-715.
127. Lorrain DS, Baccei CS, Bristow LJ, Anderson JJ, Varney MA. Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 2003;117:697-706.
128. Ichikawa J, Chung YC, Li Z, Dai J, Meltzer HY. Cholinergic modulation of basal and amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Brain Res 2002;958:176-184.
129. Zant JC, Leenaars CHC, Kostin A, Van Someren EJW, Porkka-Heiskanen T. Increases in extracellular serotonin and dopamine metabolite levels in the basal forebrain during sleep deprivation. Brain Res 2011;1399:40-48.
130. Luo J, Min S, Wei K, Cao J, Wang B, Li P et al. Behavioral and molecular responses to electroconvulsive shock differ between genetic and environmental rat models of depression. Psychiatry Res 2015;226:451-460.
131. Tanis KQ, Duman RS, Newton SS. CREB binding and activity in brain: regional specificity and induction by electroconvulsive seizure. Biol Psychiatry 2008;63:710-720.
132. Jeon SH, Seong YS, Juhnn YS, Kang UG, Ha KS, Kim YS et al. Electroconvulsive shock increases the phosphorylation of cyclic AMP response element binding protein at Ser-133 in rat hippocampus but not in cerebellum. Neuropharmacology 1997;36:411-414.
133. Zhou W, Wang N, Yang C, Li X-M, Zhou Z-Q, Yang J-J. Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex. Eur Psychiatry 2014;29:419-423.
134. Wu Y-Y, Wang X, Tan L, Liu D, Liu X-H, Wang Q et al. Lithium attenuates scopolamine-induced memory deficits with inhibition of GSK-3β and preservation of postsynaptic components. J Alzheimers Dis 2013;37:515-527.
135. Guo L, Guo Z, Luo X, Liang R, Yang S, Ren H et al. Phosphodiesterase 10A inhibition attenuates sleep deprivation-induced deficits in long-term fear memory. Neurosci Lett 2016;635:44-50.
136. Su X, Wang C, Wang X, Han F, Lv C, Zhang X. Sweet dream liquid chinese medicine ameliorates learning and memory deficit in a rat model of paradoxical sleep deprivation through the ERK/CREB signaling pathway. J Med Food 2016;19:472-480.
137. Guzman-Marin R, Ying Z, Suntsova N, Methippara M, Bashir T, Szymusiak R et al. Suppression of hippocampal plasticity-related gene expression by sleep deprivation in rats. J Physiol 2006;575:807-819.
138. Zhao W, Wang J, Bi W, Ferruzzi M, Yemul S, Freire D et al. Novel application of brain-targeting polyphenol compounds in sleep deprivation-induced cognitive dysfunction. Neurochem Int 2015;89:191-197.
139. Alkadhi KA, Alhaider IA. Caffeine and REM sleep deprivation: Effect on basal levels of signaling molecules in area CA1. Mol Cell Neurosci 2016;71:125-131.
140. Alhaider IA, Alkadhi KA. Caffeine treatment prevents rapid eye movement sleep deprivation-induced impairment of late-phase long-term potentiation in the dentate gyrus. Eur J Neurosci 2015;42:2843-2850.
141. Azogu I, de la Tremblaye PB, Dunbar M, Lebreton M, LeMarec N, Plamondon H. Acute sleep deprivation enhances avoidance learning and spatial memory and induces delayed alterations in neurochemical expression of GR, TH, DRD1, pCREB and Ki67 in rats. Behav Brain Res 2015;279:177-190.
142. Vollmayr B, Faust H, Lewicka S, Henn FA. Brain-derived-neurotrophic-factor (BDNF) stress response in rats bred for learned helplessness. Mol Psychiatry 2001;6:471-474.
143. Conti B, Maier R, Barr AM, Morale MC, Lu X, Sanna PP et al. Region-specific transcriptional changes following the three antidepressant treatments electro convulsive therapy, sleep deprivation and fluoxetine. Mol Psychiatry 2007;12:167-189.
144. Jacobsen JPR, Mørk A. The effect of escitalopram, desipramine, electroconvulsive seizures and lithium on brain-derived neurotrophic factor mRNA and protein expression in the rat brain and the correlation to 5-HT and 5-HIAA levels. Brain Res 2004;1024:183-192.
145. Newton SS, Collier EF, Hunsberger J, Adams D, Terwilliger R, Selvanayagam E et al. Gene profile of electroconvulsive seizures: induction of neurotrophic and angiogenic factors. J Neurosci 2003;23:10841-10851.
146. Altar CA, Whitehead RE, Chen R, Wörtwein G, Madsen TM. Effects of electroconvulsive seizures and antidepressant drugs on brain-derived neurotrophic factor protein in rat brain. Biol Psychiatry 2003;54:703-709.
147. Moshe H, Gal R, Barnea-Ygael N, Gulevsky T, Alyagon U, Zangen A. Prelimbic stimulation ameliorates depressive-like behaviors and increases regional BDNF expression in a novel drug-resistant animal model of depression. Brain Stimul 2016;9:243-250.
148. Hidaka N, Suemaru K, Takechi K, Li B, Araki H. Inhibitory effects of valproate on impairment of Y-maze alternation behavior induced by repeated electroconvulsive seizures and c-Fos protein levels in rat brains. Acta Med Okayama 2011;65:269-277.
149. Sartorius A, Hellweg R, Litzke J, Vogt M, Dormann C, Vollmayr B et al. Correlations and discrepancies between serum and brain tissue levels of neurotrophins after electroconvulsive treatment in rats. Pharmacopsychiatry 2009;42:270-276.
150. Taliaz D, Nagaraj V, Haramati S, Chen A, Zangen A. Altered brain-derived neurotrophic factor expression in the ventral tegmental area, but not in the hippocampus, is essential for antidepressant-like effects of electroconvulsive therapy. Biol Psychiatry 2013;74:305-312.
151. Luo J, Min S, Wei K, Zhang J, Liu Y. Propofol interacts with stimulus intensities of electroconvulsive shock to regulate behavior and hippocampal BDNF in a rat model of depression. Psychiatry Res 2012;198:300-306.
152. O'Donovan S, Kennedy M, Guinan B, O'Mara S, McLoughlin DM. A comparison of brief pulse and ultrabrief pulse electroconvulsive stimulation on rodent brain and behaviour. Prog Neuropsychopharmacol Biol Psychiatry 2012;37:147-152.
153. Gersner R, Toth E, Isserles M, Zangen A. Site-specific antidepressant effects of repeated subconvulsive electrical stimulation: potential role of brain-derived neurotrophic factor. Biol Psychiatry 2010;67:125-132.
154. Balu DT, Hoshaw BA, Malberg JE, Rosenzweig-Lipson S, Schechter LE, Lucki I. Differential regulation of central BDNF protein levels by antidepressant and nonantidepressant drug treatments. Brain Res 2008;1211:37-43.
155. Li B, Suemaru K, Cui R, Araki H. Repeated electroconvulsive stimuli have longlasting effects on hippocampal BDNF and decrease immobility time in the rat forced swim test. Life Sci 2007;80:1539-1543.
156. Angelucci F, Aloe L, Jiménez-Vasquez P, Mathé AA. Electroconvulsive stimuli alter the regional concentrations of nerve growth factor, brain-derived neurotrophic factor, and glial cell line-derived neurotrophic factor in adult rat brain. J ECT 2002;18:138-143.
157. Chen AC, Shin KH, Duman RS, Sanacora G. ECS-Induced mossy fiber sprouting and BDNF expression are attenuated by ketamine pretreatment. J ECT 2001;17:27-32.
158. Zetterström TS, Pei Q, Grahame-Smith DG. Repeated electroconvulsive shock extends the duration of enhanced gene expression for BDNF in rat brain compared with a single administration. Brain Res Mol Brain Res 1998;57:106-110.
159. Lindefors N, Brodin E, Metsis M. Spatiotemporal selective effects on brainderived neurotrophic factor and trkB messenger RNA in rat hippocampus by electroconvulsive shock. Neuroscience 1995;65:661-670.
160. Kang UG, Koo YJ, Jeon WJ, Park DB, Juhnn YS, Park JB et al. Activation of extracellular signal-regulated kinase signaling by chronic electroconvulsive shock in the rat frontal cortex. Psychiatry Res 2006;145:75-78.
161. Dyrvig M, Christiansen SH, Woldbye DPD, Lichota J. Temporal gene expression profile after acute electroconvulsive stimulation in the rat. Gene 2014;539:8-14.
162. Zhang H, Xue W, Wu R, Gong T, Tao W, Zhou X et al. Rapid antidepressant activity of ethanol extract of gardenia jasminoides ellis is associated with upregulation of BDNF expression in the hippocampus. Evid Based Complement Altern Med 2015;2015:761238.
163. Becker A, Grecksch G, Schwegler H, Roskoden T. Expression of mRNA of neurotrophic factors and their receptors are significantly altered after subchronic ketamine treatment. Med Chem 2008;4:256-263.
164. Fujihara H, Sei H, Morita Y, Ueta Y, Morita K. Short-term sleep disturbance enhances brain-derived neurotrophic factor gene expression in rat hippocampus by acting as internal stressor. J Mol Neurosci 2003;21:223-232.
165. Hansen HH, Rantamäki TPJ, Larsen MH, Woldbye DPD, Mikkelsen JD, Castrén EH. Rapid activation of the extracellular signal-regulated kinase 1/2 (ERK1/2) signaling pathway by electroconvulsive shock in the rat prefrontal cortex is not associated with TrkB neurotrophin receptor activation. Cell Mol Neurobiol 2007;27:585-594.
166. Liu R-J, Fuchikami M, Dwyer JM, Lepack AE, Duman RS, Aghajanian GK. GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine. Neuropsychopharmacology 2013;38:2268-2277.
167. Moosavi M, Khales GY, Abbasi L, Zarifkar A, Rastegar K. Agmatine protects against scopolamine-induced water maze performance impairment and hippocampal ERK and Akt inactivation. Neuropharmacology 2012;62:2018-2023.
168. Ravassard P, Pachoud B, Comte J-C, Mejia-Perez C, Scoté-Blachon C, Gay N et al. Paradoxical (REM) sleep deprivation causes a large and rapidly reversible decrease in long-term potentiation, synaptic transmission, glutamate receptor protein levels, and ERK/MAPK activation in the dorsal hippocampus. Sleep 2009;32:227-240.
169. Fujiki M, Abe E, Nagai Y, Shiqi K, Kubo T, Ishii K et al. Electroconvulsive seizureinduced VEGF is correlated with neuroprotective effects against cerebral infarction: involvement of the phosphatidylinositol-3 kinase/Akt pathway. Exp Neurol 2010;225:377-383.
170. Kang UG, Roh M-S, Jung J-R, Shin SY, Lee YH, Park J-B et al. Activation of protein kinase B (Akt) signaling after electroconvulsive shock in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:41-44.
171. Navarria A, Wohleb ES, Voleti B, Ota KT, Dutheil S, Lepack AE et al. Rapid antidepressant actions of scopolamine: role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors. Neurobiol Dis 2015;82:254-261.
172. Basar K, Eren-Kocak E, Ozdemir H, Ertugrul A. Effects of acute and chronic electroconvulsive shocks on glycogen synthase kinase 3β level and phosphorylation in mice. J ECT. 2013;29:265-270.
173. Roh M-S, Kang UG, Shin SY, Lee YH, Jung HY, Juhnn Y-S et al. Biphasic changes in the Ser-9 phosphorylation of glycogen synthase kinase-3beta after electroconvulsive shock in the rat brain. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1-5.
174. Grønli J, Dagestad G, Milde AM, Murison R, Bramham CR. Post-transcriptional effects and interactions between chronic mild stress and acute sleep deprivation: regulation of translation factor and cytoplasmic polyadenylation elementbinding protein phosphorylation. Behav Brain Res 2012;235:251-262.
175. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997;17:2921-2927.
176. Chowdhury GMI, Zhang J, Thomas M, Banasr M, Ma X, Pittman B et al. Transiently increased glutamate cycling in rat PFC is associated with rapid onset of antidepressant-like effects. Mol Psychiatry 2016;22:120-126.
177. Xie F, Li X, Bao M, Shi R, Yue Y, Guan Y et al. Anesthetic propofol normalized the increased release of glutamate and γ-amino butyric acid in hippocampus after paradoxical sleep deprivation in rats. Neurol Res 2015;37:1102-1107.
178. Elfving B, Bonefeld BE, Rosenberg R, Wegener G. Differential expression of synaptic vesicle proteins after repeated electroconvulsive seizures in rat frontal cortex and hippocampus. Synapse 2008;62:662-670.
179. Luo J, Min S, Wei K, Cao J, Wang B, Li P et al. Propofol prevents electroconvulsiveshock- induced memory impairment through regulation of hippocampal synaptic plasticity in a rat model of depression. Neuropsychiatr Dis Treat 2014;10:1847-1859.